Results 211 to 220 of about 514,530 (316)

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA Repair. [PDF]

Int J Biol Sci
Corno C, Costantino M, Pettinari P, Mirra L, Stucchi S, Arrighetti N, Perta N, Di Muccio G, Robin M, Beretta GL, Corna E, Carenini N, Cleris L, Colombo D, Luison E, Ciniselli CM, Lecchi M, Verderio P, Figini M, Linder S, Tosi D, La Teana A, D'Arcy P, Perego P.   +23 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Development of an Active Chimeric IL13Rα2 ADC for Diffuse Intrinsic Pontine Glioma. [PDF]

Immunotargets Ther
Lian X, Allanson VJ, Rasmussen SV, Chauhan S, Tan GK, Morrow P, Hanson K, Lian EB, Haight AR, Hoshino T, Liu X, Berlow NE, Keller C, Lian Y.   +13 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Spriano F, Cascione L, Tarantelli C, Sartori G, Arribas AJ, Velasova A, Napoli S, Havranek O, Toretsky JA, Bertoni F.   +9 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Multiple sclerosis-associated HLA demarcates EBV-specific CD8⁺ T cells with an exhausted and brain residency phenotype. [PDF]

iScience
Reijm S, Marques AM, Rip J, Corsten CEA, Wierenga-Wolf AF, de Wit H, Melief MJ, van Hasselt Y, van Langelaar J, Neuteboom R, Wokke BHA, Mueller YM, Smolders J, van Luijn MM.   +13 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Protocol for mapping murine myeloid bone marrow progenitors and their differentiation into CD103⁺ cDC1s and CD301b⁺ cDC2s. [PDF]

STAR Protoc
Vurnek D, Tchitashvili G, Seichter A, Vuletic T, Heß I, Trapaidze L, Heger L, Tochoedo NR, Lehmann CHK, Lambrecht BN, Dudziak D, Amon L.   +11 more
europepmc   +1 more source